Sebastian Bauer
A5031540987- Gastrointestinal Tumor Research and Treatment
- Sarcoma Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Gastrointestinal disorders and treatments
- Peptidase Inhibition and Analysis
- Vascular Tumors and Angiosarcomas
- X-ray Diffraction in Crystallography
- Crystallization and Solubility Studies
- Chronic Myeloid Leukemia Treatments
- Cardiac tumors and thrombi
- Cancer Genomics and Diagnostics
- Neurofibromatosis and Schwannoma Cases
- Platelet Disorders and Treatments
- Metastasis and carcinoma case studies
- Cancer, Hypoxia, and Metabolism
- Cancer, Lipids, and Metabolism
- Lymphoma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Bone Tumor Diagnosis and Treatments
- Musculoskeletal synovial abnormalities and treatments
- Histone Deacetylase Inhibitors Research
- Extracellular vesicles in disease
- Advanced Breast Cancer Therapies
- Multiple Myeloma Research and Treatments
- Radiopharmaceutical Chemistry and Applications
Essen University Hospital
2016-2025
Deutschen Konsortium für Translationale Krebsforschung
2016-2025
University of Duisburg-Essen
2016-2025
German Cancer Research Center
2016-2025
West Cancer Center
2016-2025
Brigham and Women's Hospital
2005-2024
Heidelberg University
1990-2024
West German Heart and Vascular Center Essen
2015-2024
TU Dortmund University
2013-2024
Science for Life Laboratory
2023-2024
Soft tissue sarcomas (STSs) gather over 80 histological entities, with even more molecular subsets, characterised by a low to very incidence in all populations. The majority of arise from the soft (close 75%), ∼15% gastrointestinal stromal tumours (GISTs) and 10% bone sarcomas. These ESMO–EURACAN (European Society for Medical Oncology–European Reference Network rare adult solid cancers) Clinical Practice Guidelines cover STSs, while GISTs are covered dedicated [1.Casali P.G. Abecassis N....
<h3>Context</h3>Adjuvant imatinib administered for 12 months after surgery has improved recurrence-free survival (RFS) of patients with operable gastrointestinal stromal tumor (GIST) compared placebo.<h3>Objective</h3>To investigate the role administration duration as adjuvant treatment who have a high estimated risk GIST recurrence surgery.<h3>Design, Setting, and Patients</h3>Patients KIT-positive removed at were entered between February 2004 September 2008 to this randomized, open-label...
Gastrointestinal stromal tumours (GISTs) are rare tumours, with an estimated unadjusted incidence of around 1/100 000/year [1.Nilsson B. Bümming P. Meis-Kindblom J.M. et al.Gastrointestinal tumors: the incidence, prevalence, clinical course, and prognostication in preimatinib mesylate era–a population-based study western Sweden.Cancer. 2005; 103: 821-829Crossref PubMed Scopus (1027) Google Scholar]. This only covers clinically relevant GISTs, since, if investigated, a much higher number...
Primary bone tumours are rare, accounting for < 0.2% of malignant neoplasms registered in the EUROCARE (European Cancer Registry based study on survival and care cancer patients) database [1.Stiller C.A. Trama A. Serraino D. Descriptive epidemiology sarcomas Europe: report from RARECARE project.Eur J Cancer. 2013; 49: 684-695Abstract Full Text PDF PubMed Scopus (265) Google Scholar]. Different tumour subtypes have distinct patterns incidence, each has no more than 0.3 incident cases per 100...
Leiomyosarcoma (LMS) is an aggressive mesenchymal malignancy with few therapeutic options. The mechanisms underlying LMS development, including clinically actionable genetic vulnerabilities, are largely unknown. Here we show, using whole-exome and transcriptome sequencing, that tumors characterized by substantial mutational heterogeneity, near-universal inactivation of TP53 RB1, widespread DNA copy number alterations chromothripsis, frequent whole-genome duplication. Furthermore, detect...
Three years of adjuvant imatinib therapy are recommended for patients with GI stromal tumor (GIST) high-risk features, according to survival findings in the Scandinavian Sarcoma Group XVIII/AIO (Arbeitsgemeinschaft Internistische Onkologie) trial. To investigate whether benefits have persisted, we performed second planned analysis trial.Eligible had macroscopically completely excised, KIT-positive GIST a high risk recurrence, as determined by using modified National Institutes Health...
Abstract The clinical relevance of comprehensive molecular analysis in rare cancers is not established. We analyzed the profiles and outcomes 1,310 patients (rare cancers, 75.5%) enrolled a prospective observational study by German Cancer Consortium that applies whole-genome/exome RNA sequencing to inform care adults with incurable cancers. On basis 472 single six composite biomarkers, cross-institutional tumor board provided evidence-based management recommendations, including diagnostic...
Little is known about whether the duration of adjuvant imatinib influences prognostic significance KIT proto-oncogene receptor tyrosine kinase (KIT) and platelet-derived growth factor α (PDGFRA) mutations.To investigate effect PDGFRA mutations on recurrence-free survival (RFS) in patients with gastrointestinal stromal tumors (GISTs) treated surgery imatinib.This exploratory study based Scandinavian Sarcoma Group VIII/Arbeitsgemeinschaft Internistische Onkologie (SSGXVIII/AIO) multicenter...